1. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: A retrospective study from the European Group for Blood and Marrow Transplantation
- Author
-
Roos-Weil, D. (Damien), Dietrich, S. (Sascha), Boumendil, A. (Ariane), Polge, E. (Emmanuelle), Bron, D. (Dominique), Carreras, E. (Enric), Atienza, A.I. (Arturo Iriondo), Arcese, W. (William), Beelen, D.W. (Dietrich), Cornelissen, J.J. (Jan), Kröger, N. (Nicolaus), Milone, G. (Gustavo), Rossi, G. (Giulio) de, Jardin, F. (Fabrice), Peters, C. (Christina), Rocha, V. (Vanderson), Sureda, A. (Anna), Mohty, M. (Mohamad), Dreger, P. (Peter), Roos-Weil, D. (Damien), Dietrich, S. (Sascha), Boumendil, A. (Ariane), Polge, E. (Emmanuelle), Bron, D. (Dominique), Carreras, E. (Enric), Atienza, A.I. (Arturo Iriondo), Arcese, W. (William), Beelen, D.W. (Dietrich), Cornelissen, J.J. (Jan), Kröger, N. (Nicolaus), Milone, G. (Gustavo), Rossi, G. (Giulio) de, Jardin, F. (Fabrice), Peters, C. (Christina), Rocha, V. (Vanderson), Sureda, A. (Anna), Mohty, M. (Mohamad), and Dreger, P. (Peter)
- Abstract
Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have a poor prognosis with conventional chemotherapy. In the present study, we retrospectively analyzed the outcome of patients with BPDCN who underwent allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT). A total of 39 patients (allo-SCT, n = 34; auto-SCT, n = 5) were identified in the European Group for Blood and Marrow Transplantation registry. The 34 allo-SCT patients had a median age of 41 years (range, 10-70) and received transplantations from sibling (n = 11) or unrelated donors (n = 23) between 2003 and 2009. MAC was used in 74% of patients. Nineteen allo-SCT patients (56%) received transplantations in first complete remission. The 3-year cumulative incidence of relapse, disease-free survival, and overall survival was 32%, 33%, and 41%, respectively. By univariate comparison, being in first remission at allo-SCT favorably influenced survival, whereas age, donor source, and chronic GVHD had no significant impact. We conclude that high-dose therapy followed by allo-SCT from related or unrelated donors
- Published
- 2013
- Full Text
- View/download PDF